VAI-SU2C Epigenetics Dream Team
33 results.
With 2017 quickly coming to close, we’d like to reflect on all that’s been accomplished by rounding up some of this year’s most notable stories…
A first-of-its-kind combination of medications may enable the immune system to better combat lung cancer, which claims more lives than any other cancer type and…
Nearly $5.5 million in grant funding to fuel collaborative clinical trials in lung and bladder cancers By Dr. Peter Jones and Dr. Steve Baylin Co-leaders,…
GRAND RAPIDS, Mich. (Oct. 12, 2017)—Van Andel Research Institute–Stand Up To Cancer Epigenetics Dream Team (VARI-SU2C) scientists have been awarded two…
GRAND RAPIDS, Mich. (June 13, 2017)—A new clinical trial spanning three cancer centers in California, Maryland and Pennsylvania is investigating a promising…
VARI-affiliated cancer researcher Stephen Baylin, M.D., has been elected to the National Academy of Sciences…
Safety and efficacy of combining talazoparib with decitabine to treat acute myeloid leukemia (AML) are subject of multi-site clinical trial
GRAND RAPIDS, Mich. (March 7,…
March marks Colorectal Cancer Awareness Month, a time to share information and raise awareness about these devastating diseases. Here are three key…